Vyne Therapeutics
Late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus. Learn more
Launch date
Employees
Market cap
€24.0m
Enterprise valuation
(€47m) (Public information from Sep 2024)
Share price
$1.9 VYNE
Menlo Park California (HQ)
Authorizing premium user...